Show simple item record

dc.contributor.authorCORVIN, AIDEN PETERen
dc.date.accessioned2013-08-07T15:40:55Z
dc.date.available2013-08-07T15:40:55Z
dc.date.issued2011en
dc.date.submitted2011en
dc.identifier.citationZhou, K., Bellenguez, C., Spencer, C.C.A., Bennett, A.J., Coleman, R.L., Tavendale, R., Hawley, S.A., (...), Pearson, E.R., Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes, Nature Genetics, 43, 2, 2011, 117-120en
dc.identifier.otherYen
dc.descriptionPUBLISHEDen
dc.descriptionPubMed ID: 21186350en
dc.description.abstractMetformin is the most commonly used pharmacological therapy for type 2 diabetes. We carried out a GWA study on glycaemic response to metformin in 1024 Scottish patients with type 2 diabetes. Replication was in two cohorts consisting of 1783 Scottish patients and 1113 patients from the UK Prospective Diabetes Study. In a meta-analysis (n=3920) we observed an association (P=2.9 *10 ?9 ) for a SNP rs11212617 at a locus containing the ataxia telangiectasia mutated ( ATM ) gene with an odds ratio of 1.35 (95% CI 1.22 to 1.49) for treatment success. In a rat hepatoma cell line, inhibition of ATM with KU-55933 attenuated the phosphorylation and activation of AMPK in response to metformin. We conclude that ATM, a gene known to beinvolved in DNA repair and cell cycle control, plays a role in the effect of metformin upstream of AMPK, and variation in this gene alters glycaemic response to metforminen
dc.description.sponsorshipWe are grateful to all the participants who took part in this study, to the general practitioners, to the Scottish School of Primary Care for their help in recruiting the participants, and to the whole team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists, and nurses. The Wellcome Trust provides support for Wellcome Trust United Kingdom Type 2 Diabetes Case Control Collection (GoDARTS) and informatics support is provided by the Chief Scientist Office. The Wellcome Trust funds the Scottish Health Informatics Programme, provides core support for the Wellcome Trust Centre for Human Genetics in Oxford and funds the Wellcome Trust Case Control Consortium 2. This research was specifically funded by Diabetes UK (07/0003525), MRC (G0601261) and the Wellcome Trust (084726/Z/08/Z, 085475/Z/08/Z, 085475/B/08/Z). We also acknowledge support from the NIHR award to Moorfields Eye Hospital NHS Foundation Trust and University College London Institute of Ophthalmology for a Specialist Biomedical Research Centre for Ophthalmology (ACV). P. Donnelly was supported in part by a Wolfson?Royal Society Merit Award. KZ holds a Henry Wellcome Post-Doctoral Fellowship. SAH and DGH were supported by the EXGENESIS consortium (LSHM-CT-2004-005272) funded by the European Commissionen
dc.format.extent117-120en
dc.language.isoenen
dc.relation.ispartofseriesNature Geneticsen
dc.relation.ispartofseries43en
dc.relation.ispartofseries2en
dc.rightsYen
dc.subjectglycaemic responsen
dc.subject.lcshglycaemic responsen
dc.titleCommon variants near ATM are associated with glycemic response to metformin in type 2 diabetesen
dc.typeJournal Articleen
dc.type.supercollectionscholarly_publicationsen
dc.type.supercollectionrefereed_publicationsen
dc.identifier.peoplefinderurlhttp://people.tcd.ie/acorvinen
dc.identifier.rssinternalid73741en
dc.contributor.sponsorMedical Research Council (MRC)en
dc.contributor.sponsorGrantNumberG0601261en
dc.contributor.sponsorWellcome Trusten
dc.contributor.sponsorGrantNumber085475/Z/08/Zen
dc.contributor.sponsorWellcome Trusten
dc.contributor.sponsorGrantNumber085475/B/08/Zen
dc.contributor.sponsorWellcome Trusten
dc.contributor.sponsorGrantNumber084726/Z/08/Zen
dc.contributor.sponsorNational Institutes of Health (NIH)en
dc.identifier.urihttp://hdl.handle.net/2262/66912


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record